Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is approved in the United States and Europe for the treatment of refractory metastatic colorectal cancer (mCRC). Skin toxicities are the most common adverse events with EGFR inhibitors. This is the first study designed to examine differences between pre-emptive and reactive skin treatment for specific skin toxicities in patients with mCRC for any EGFR inhibitor.
INTRODUCTION
The discovery that the epidermal growth factor receptor (EGFR) is overexpressed in 70% to 80% of patients with advanced colorectal cancer (CRC) and that its dysregulation is associated with decreased survival and poor prognosis has resulted in the development and use of EGFR inhibitors (EGFRIs) in CRC. 1, 2 A phase III study demonstrated that panitumumab, a fully human monoclonal antibody (mAb) administered as monotherapy for the treatment of chemorefractory CRC, was active and well tolerated when compared to best supportive care. 3 Cetuximab, a chimeric mAb, has activity as monotherapy, or when added to irinotecan for irinotecan-refractory mCRC, in patients with EGFRpositive tumors. 4, 5 EGFRIs represent a new option for patients with disease progression on fluorouracil (FU), irinotecan, and oxaliplatin regimens. 6 Tumor control, patient survival, and decreased hematopoietic toxicity benefits contributed significantly to EGFRI therapy integration into protocols; however, use of these agents has been hampered by a constellation of dermatologic toxicities in more than 90% of patients, most notably a papulopustular rash, xerosis, pruritus, and paronychia, as JOURNAL OF CLINICAL ONCOLOGY common on-target toxicities. 7, 8 Though rarely life-threatening, these untoward events impact quality of life (QOL), increase patient risk for additional infections, and lead to inconsistent EGFRI administration, all of which may affect clinical outcomes.
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Management of skin toxicities in EGFRI-treated patients is critical to ensure EGFRI dose intensity and maintain QOL. Moreover, since a correlation between rash severity and survival has been established, it is essential that antitoxicity interventions do not interfere with antitumor activity of EGFRIs. 12 Phase III trials have demonstrated that tetracycline and minocycline decrease the severity of papulopustular rash. 13, 14 We designed this randomized, phase II study of pre-emptive skin toxicity therapy compared with reactive treatment to evaluate the effect of comprehensive skin toxicity management in patients with CRC treated with panitumumab combined with irinotecan or FOLFIRI (leucovorin, fluorouracil, and irinotecan).
PATIENTS AND METHODS

Patients
Eligible patients had metastatic adenocarcinoma of the colon or rectum with at least one unidimensional measurable lesion greater than or equal to 20 mm using conventional techniques (magnetic resonance imaging or computed tomography scan) or greater than or equal to 10 mm using a spiral CT scan that could not, per investigator assessment, be cured by surgical resection. Patients also had disease progression or unacceptable toxicity with first-line treatment containing fluoropyrimidine and oxaliplatin-based chemotherapy with or without bevacizumab for mCRC.
Other key eligibility criteria included Ն 18 years old, an Eastern Cooperative Oncology Group performance status of 0 or 1, and adequate hematologic, renal, metabolic, and hepatic function. No prior irinotecan treatment or anti-EGFR therapy or vaccine treatment for mCRC, and no incidence of pulmonary embolism, deep vein thrombosis, or any other significant thromboembolic event within 8 weeks before random assignment were allowed. Each center's institutional review board approved the study protocol and informed consent form. Before any study-specific procedures, patients understood and signed the informed consent.
Study Design and Treatment Schedule
This was a phase II, multicenter, open-label, randomized clinical trial conducted in the United States. The sample size was chosen to provide a preliminary estimate of the difference in incidence of specific Ն grade 2 skin toxicities of interest between patients in the pre-emptive and reactive skin treatment arms. Eligible patients were randomly assigned 1:1 to pre-emptive or reactive skin treatment. Chemotherapy regimen schedule was a random assignment stratification factor. The pre-emptive skin treatment regimen was administered beginning day Ϫ1 (one day before the administration of the first panitumumab dose) and continued through weeks 1 to 6, and consisted of skin moisturizer applied to face, hands, feet, neck, back, and chest daily in the morning on rising; sunscreen (PABA free, SPF Ն 15, UVA and UVB protection) applied to exposed skin areas before going outdoors; topical steroid (1% hydrocortisone cream) applied to face, hands, feet, neck, back, and chest at bedtime; and doxycycline 100 mg twice per day. All patients were given an instructional video that provided suggestions to reduce skin irritation. For patients randomly assigned to the pre-emptive arm, the instructional video also included instructions for the application of the skin moisturizer, sunscreen, and topical steroid. The reactive skin treatment regimen consisted of any treatments the investigator deemed necessary for the management of emergent skin toxicity and could be administered at any time during weeks 1 to 6. Patients randomly assigned to the reactive skin treatment regimen were not prohibited from using skin moisturizer or sunscreen at any time during the study if they chose to do so. All patients were monitored weekly from weeks 1 to 7 for compliance with the randomized skin treatment regimen and for skin toxicity assessment. Throughout the skin treatment period, patients completed a daily diary of symptoms and treatment compliance. This diary was shared with study personnel at each weekly clinic visit and was used for case report form data entry. From week 7 and thereafter, investigators had the option to continue patients on the assigned skin treatment regimen.
Panitumumab was administered at 6.0 mg/kg every 2 weeks with FOLFIRI chemotherapy and at 9.0 mg/kg every 3 weeks with irinotecan chemotherapy; the chemotherapy regimen was chosen by the investigator. Tumor responses were evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) with modifications based on current practices in the medical community and were performed by blinded central review at weeks 9 and 13, and then every 8 weeks for patients on the every 2 week regimen, and at weeks 10, 14, 22 and then every 9 weeks for patients on the every 3 week regimen (Figs 1 [CONSORT] and 2). 15 Patients continued on-study until completion of the post-treatment follow-up period, death, withdrawal of full consent, or until lost to follow-up.
Patient-reported QOL was assessed using the Dermatology Life Quality Index (DLQI) at screening, weeks 2 to 7, and at the week 13 or 14 visit, depending on the treatment schedule. The DLQI consists of 10 simple questions to assess QOL in patients with skin disorders, and is scored on a scale of 0 to 30; higher scores indicate more QOL impairment.
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Study Objectives
The primary objective of this study was to estimate the difference in incidence of specific Ն grade 2 skin toxicities of interest between patients in the pre-emptive and reactive skin treatment groups during the 6-week skin treatment period. Protocol-defined skin toxicities of interest included pruritus, acneifom dermatitis, skin desquamation, exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. Key secondary objectives included an assessment of the incidence rates of skin toxicities of any type during the 6-week skin treatment period and an assessment of the efficacy and safety of panitumumab given concomitantly with second-line irinotecan chemotherapy.
At the time this study was designed, information on the impact of KRAS status on panitumumab activity was not available; however, as the study progressed, these data became available and analysis of KRAS status was done. The groups were found to be generally well-balanced with respect to KRAS status between arms, with 52% wild-type (n ϭ 23) and 48% mutant (n ϭ 21) in the pre-emptive group, and 60% wild-type (n ϭ 26) and 40% mutant (n ϭ 17) in the reactive group. Results by chemotherapy regimen and KRAS status will be reported separately.
Statistical Analysis
This analysis was performed when all randomly assigned patients (n ϭ 95) completed the study. This is the final analysis of the primary end point of skin toxicity, antitumor efficacy, QOL, and safety by skin treatment regimen for all randomly assigned patients.
Descriptive statistics for the primary end point, including 95% CIs obtained via normal approximation to the binomial distribution, were analyzed for each skin treatment arm. A logistic regression model using treatment group (pre-emptive v reactive) and chemotherapy (every 2 week v every 3 week) as covariates was used to estimate the treatment effect on the primary end point. The odds ratio (OR) and 95% CIs using the Wald method were provided.
For time-to-event end points (time to first skin toxicity of interest, PFS, and OS), Kaplan-Meier (KM) plots, KM estimates, and associated 95% CIs were analyzed. Comparison of the treatment effect on time-to-event end points was based on the hazard ratio (HR) from the Cox regression models stratified by chemotherapy regimen (every 2 weeks v every 3 weeks). Estimates of HR and 95% CI were also included.
Skin-related QOL was assessed using the DLQI. The DLQI was summarized by change from baseline to week 3 (the peak of skin toxicity) and week 7 (the last skin toxicity assessment during the skin treatment period).
Adverse events were grouped by system organ class using the Medical Dictionary for Regulatory Activities (MedDRA) version 9.0 and graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 except for panitumumab-related skin toxicities which were graded using a modified Common Terminology Criteria for Adverse Events version 3.0.
RESULTS
Patients
A total of 95 patients were enrolled and randomly assigned, 48 received the pre-emptive skin treatment regimen (51%) and 47 received the reactive skin treatment regimen (49%). As of the data cutoff date (September 3, 2008) for this analysis, all patients had discontinued second-line treatment; the most common reason was disease progression (30 patients in the pre-emptive group, 28 patients in the reactive group). Demographics and disease characteristics were wellbalanced between treatment groups. In this small phase II study, the randomization was not stratified for demographics which resulted in small differences between the distribution of sex and race between treatment groups. Outcomes were not believed to be impacted by these differences. 17 Median follow-up time was 31.0 and 40.7 weeks for the pre-emptive and reactive skin treatment groups, respectively (Table 1) .
Primary End Point
In the pre-emptive group, the incidence of specific Ն grade 2 skin toxicities was 29% compared with 62% in the reactive group (OR, 0.3; 95% CL, 0.1 to 0.6), resulting in a more than 50% decrease in these toxicities in the pre-emptive versus reactive groups. Grade 2 skin toxicities of interest were reported in 23% of patients in the preemptive group and 40% of patients in the reactive group. A similar trend was observed for the grade 3 skin toxicities of interest, with 6% and 21% of patients in the pre-emptive and reactive groups experiencing grade 3 events, respectively. Total panitumumab doses administered were 155 in the pre-emptive group compared with 141 in the reactive group during the skin treatment period, and panitumumab dose delays were observed in one and nine patients in the pre-emptive and reactive groups, respectively ( Table 2) .
Median time to first occurrence of specific Ն grade 2 skin toxicities of interest was not reached in the pre-emptive group and was 2.1 (95% CL, 2.1 to 6.3) weeks in the reactive group (Fig 3) .
Antitumor Efficacy
Seven patients (15%) in the pre-emptive group had a partial response compared with 5 (11%) patients in the reactive group. The stable disease rate was similar in the pre-emptive (50%) and reactive groups (53%). Disease control and disease progression were also similar between groups. Median progression-free survival time was 4.7 months (95% CI, 2.9 to 6.0) in the pre-emptive group and 4.1 months (95% CI, 2.9 to 6.2) in the reactive group (HR, 1.0; 95% CI, 0.6 to 1.6; Table 3 ).
Safety
All patients experienced at least one adverse event. In the preemptive group, 60% of patients experienced a maximum grade 3 or higher adverse event versus 81% of patients in the reactive group. A similar trend was observed with serious adverse events (SAE) in the pre-emptive and reactive groups, with 27% and 49% of patients experiencing an SAE, respectively.
Adverse events (any grade) commonly observed after panitumumab administration were reported less frequently in the preemptive versus the reactive group and included dermatitis acneiform (77% v 85%), pustular rash (27% v 40%), and paronychia (17% v 36%). There were no grade 5 commonly observed adverse events in either skin treatment group (Table 4) .
QOL
Results from the DLQI indicated that QOL was less impaired in the pre-emptive group compared with the reactive group. Since skin NOTE. Specific skin toxicities of interest per protocol. Abbreviation: CL, confidence limit.
‫ء‬
There were no grade 4 skin toxicities during the skin treatment period. †Odds ratio is estimated from a logistic regression model including treatment (pre-emptive v reactive) that includes an adjustment for chemotherapy stratum (every 2 weeks v every 3 weeks).
‡From week 7 and thereafter, investigators had the option to continue patients on the assigned skin treatment regimen. 
DISCUSSION
Skin toxicities to EGFRIs are characterized by pruritus, acneifom dermatitis, skin desquamation (also described as skin exfoliation), paronychia, skin fissures, pustular rash, skin infection, skin ulceration, and local infection. These toxicities occur with varying frequency and at chronologically distinct points during EGFRI therapy, with rash and pruritus developing within the first 2 weeks, followed by paronychia, desquamation, and infections at or following week 4. Rash is the most frequent toxicity, occurring in approximately 90% of patients on the EGFRI mAbs cetuximab and panitumumab and in approximately 70% of patients on the tyrosine kinase inhibitors gefitinib and erlotinib. These skin toxicities can negatively impact QOL, skin health, and result in EGFRI dose modification and discontinuation by 76% and 32%, respectively, by prescribing oncologists. 11 Because of this impact on EGFRI dose delivery, our study evaluated if preemptive therapy affects the development of Ն grade 2 skin toxicities compared to reactive therapy.
The rationale for pre-emptive therapy of skin toxicities to EGFRIs is based on the high incidence of patients who develop rash and dry skin, both of which can be complicated with infections. Although the mechanisms underlying EGFRI-induced skin toxicities are not fully understood, clinical and experimental data suggest that abnormal survival, proliferation, migration, and differentiation of epidermal cells, along with recruitment of inflammatory cells, result in the characteristic skin toxicity phenotype. 18 Histologic examination of affected skin shows abnormal keratinization of the epidermis, hair follicle rupture, abundant collections of neutrophils or mononuclear cells, and bacterial concretions within hair follicles, suggesting superinfection. 19, 20 In addition, ultraviolet radiation-induced skin damage appears to be enhanced when EGFR signaling is inhibited, demonstrated by increased sensitization of keratinocytes to apoptosis after EGFR inhibition, and the development of EGFRI rash in sun-exposed areas or areas not covered by sunscreen. [21] [22] [23] These data suggest that four major alterations occur in the skin of patients treated with EGFRIs: follicular and interfollicular inflammation, bacterial superinfection, dry skin, and sensitivity to ultraviolet radiation.
The rationale for selection of the comprehensive skin toxicity management program was based on the four alterations described above. The topical corticosteroid hydrocortisone 1% was instituted against cutaneous inflammation and pruritus; the semisynthetic tetracycline analog doxycycline for its anti-inflammatory properties through inhibition of lymphocyte proliferation, neutrophil migration, and interleukin-6 synthesis, as well as its antibacterial properties conferred by binding to the 30S ribosomal subunit in the mRNA translation complex; a moisturizer to restore the permeability barrier and to treat dry skin; and sunscreen to prevent ultraviolet radiation induced skin toxicity. [23] [24] [25] Patients in the pre-emptive arm were instructed to apply topicals daily from weeks 1 to 6, the pivotal time frame for the development of toxicities. 26 In the reactive arm, therapy was instituted if and when toxicities developed.
Reactive treatment for emergent skin toxicities minimally impacted the 62% observed rate of Ն grade 2 skin toxicities when compared to historic controls that showed rates in the 60% to 80% range for Ն grade 2 skin toxicities, underscoring the importance of pre-emptive skin toxicity treatment. 3, 4, 27 In contrast, a significant reduction of approximately 50% in the development of Ն grade 2 skin toxicities was demonstrated in the pre-emptive versus reactive arms. This difference was further demonstrated in lower rates of grade 2 and grade 3 toxicities in the pre-emptive versus reactive arms. Reductions in dermatitis acneiform, pustular rash, and pruritus are conceptually understandable owing to administered therapies; however, the Patients with any event  48  100  15  31  20  42  5  10  47  100  8  17  25  53  10  21  Dermatitis acneiform  37  77  13  27  2  4  0  0  40  85  16  34  10  21  0  0  Pruritus  30  63  10  21  1  2  0  0  32  68  13  28  5  11  0  0  Pustular rash  13  27  2  4  2  4  0  0  1 9  4 0  6  1 3  8  1 7  0  0  Paronychia  8  17  3  6  0  0  1  2  1 7  3 6  7  1 5  3  6  0  0  Nausea  32  67  14  29  3  6  0  0  26  55  8  17  4  9  0  0  Vomiting  22  46  10  21  3  6  0  0  17  36  9  19  4  9  0  0  Fatigue  29  60  12  25  5  10  0  0  27  57  11  23  5 effect on paronychia is more complex, likely due to the antiinflammatory and antibacterial effect of doxycycline, as has been reported anecdotally. 28, 29 In this analysis, non-skin toxicities that included diarrhea, dehydration, and neutropenia were also reduced in the pre-emptive arm compared to the reactive arm. Although our study was not designed to prevent or treat non-skin toxicities, these observations suggest that through pre-emptive therapy, decreased recruitment of neutrophils to the skin and maintenance of cutaneous integrity minimizes neutropenia and dehydration. It also suggests that EGFRI or chemotherapyinduced diarrhea has an inflammatory or infectious component that is potentially improved with the use of doxycycline, the only systemic agent administered. Further studies are needed to evaluate the use of doxycycline for combined EGFRI-cytotoxic therapy induced diarrhea.
The well-established correlation between rash and clinical outcome dictates that antitoxicity interventions do not impact antitumor activity of EGFRIs.
12 In this study, there was no significant difference in panitumumab median dose intensity or number of infusions between the pre-emptive and reactive treatment arms. Partial response and progression-free survival were numerically higher in the preemptive arm, though none of the observed differences were statistically significant. Further studies are warranted to explore these potential differences. No differences were observed in disease control or progression. During the skin treatment period, 1% of patients in the pre-emptive arm had panitumumab dose delays compared with 6% of patients in the reactive arm. Potential subjective benefits from the DLQI were also observed: at week 3, the peak time to develop skin toxicities; the pre-emptive skin treatment group showed a 69% improvement in QOL scores versus the reactive group. At 7 weeks however, this difference was less marked with a 23% improvement in QOL scores for the pre-emptive skin treatment group. These data suggest that pre-emptive management of skin toxicities does not affect antitumor activity and may result in improved clinical outcomes. This treatment strategy is a potential tool to minimize the need for dose modifications and improve clinical outcomes.
In summary, these findings underscore the importance of establishing a pre-emptive, comprehensive skin toxicity program in patients treated with panitumumab. Since these toxicities are considered a class-based effect, these results may be generalized to other EGFRIs. The reduction in Ն grade 2 skin toxicities, especially rash, paronychia, and pruritus, improvements in QOL, lack of interference on antitumor effect, and decreased need for dose modification justify this therapeutic rationale. Development of novel antitoxicity strategies with similar characteristics are welcome opportunities, as there are still considerable numbers of patients with Ն grade 2 skin toxicities, especially in the reactive setting. It is anticipated that the implementation of such strategies will contribute to the optimization of EGFRI therapies. 
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